Go Pro
→ If you keep cash in a U.S. bank account… read this NOW (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$2.79
+2.6%		$3.06
$1.81
▼
$4.53
$90.36M1.21707,222 shs702,321 shs
ImmuCell Corporation stock logo
ICCC
ImmuCell
$10.75
-2.9%		$10.37
$4.52
▼
$12.10
$100.15M0.5427,102 shs15,131 shs
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$3.96
+12.5%		$4.39
$2.90
▼
$23.42
$26.64M1.4116,506 shs138,698 shs
Rafael Holdings, Inc. stock logo
RFL
Rafael
$2.06
+10.4%		$2.27
$1.12
▼
$3.96
$97.24M0.33119,083 shs128,042 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
+2.57%-16.72%-5.42%+16.25%+46.46%
ImmuCell Corporation stock logo
ICCC
ImmuCell
-2.89%-2.36%+6.86%+26.92%+74.23%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
+12.50%+9.09%-2.22%-33.45%-75.93%
Rafael Holdings, Inc. stock logo
RFL
Rafael
+8.40%+4.51%-25.78%+62.52%+22.86%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$2.79
+2.6%		$3.06
$1.81
▼
$4.53
$90.36M1.21707,222 shs702,321 shs
ImmuCell Corporation stock logo
ICCC
ImmuCell
$10.75
-2.9%		$10.37
$4.52
▼
$12.10
$100.15M0.5427,102 shs15,131 shs
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$3.96
+12.5%		$4.39
$2.90
▼
$23.42
$26.64M1.4116,506 shs138,698 shs
Rafael Holdings, Inc. stock logo
RFL
Rafael
$2.06
+10.4%		$2.27
$1.12
▼
$3.96
$97.24M0.33119,083 shs128,042 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
+2.57%-16.72%-5.42%+16.25%+46.46%
ImmuCell Corporation stock logo
ICCC
ImmuCell
-2.89%-2.36%+6.86%+26.92%+74.23%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
+12.50%+9.09%-2.22%-33.45%-75.93%
Rafael Holdings, Inc. stock logo
RFL
Rafael
+8.40%+4.51%-25.78%+62.52%+22.86%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
2.25
Hold$17.00509.32% Upside
ImmuCell Corporation stock logo
ICCC
ImmuCell
1.00
SellN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2.43
Hold$56.401,324.24% Upside
Rafael Holdings, Inc. stock logo
RFL
Rafael
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest PSTV, FBIO, ICCC, and RFL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/8/2026
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
7/2/2026
ImmuCell Corporation stock logo
ICCC
ImmuCell
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/8/2026
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
Ascendiant Capital Markets logo
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$65.00 ➝ $57.00
5/28/2026
Rafael Holdings, Inc. stock logo
RFL
Rafael
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
5/18/2026
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
5/8/2026
Rafael Holdings, Inc. stock logo
RFL
Rafael
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$63.26M1.47N/AN/A$2.00 per share1.40
ImmuCell Corporation stock logo
ICCC
ImmuCell
$27.64M3.52$0.19 per share57.42$2.99 per share3.60
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/AN/AN/AN/A$0.72 per shareN/A
Rafael Holdings, Inc. stock logo
RFL
Rafael
$920K116.66N/AN/A$1.91 per share1.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$6.82M$3.170.88N/AN/A193.12%109.66%45.56%8/13/2026 (Estimated)
ImmuCell Corporation stock logo
ICCC
ImmuCell
-$1.04M-$0.06N/AN/AN/A-1.82%-1.88%-1.22%8/13/2026 (Estimated)
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$22.39M-$2.30N/AN/AN/A-230.24%-198.48%-73.13%8/13/2026 (Estimated)
Rafael Holdings, Inc. stock logo
RFL
Rafael
-$30.52M-$0.68N/AN/AN/A-3,321.74%-41.27%-35.32%N/A

Latest PSTV, FBIO, ICCC, and RFL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$0.20N/AN/AN/A$18.30 millionN/A
8/13/2026Q2 2026
ImmuCell Corporation stock logo
ICCC
ImmuCell
$0.05N/AN/AN/A$5.40 millionN/A
8/13/2026Q2 2026
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$0.88N/AN/AN/A$1.11 millionN/A
5/15/2026Q1 2026
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$0.8480-$1.05-$0.2020-$1.05$0.97 million$1.03 million
5/14/2026Q1 2026
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$0.22$2.82+$3.04$2.82$16.34 million$16.04 million
5/14/2026Q1 2026
ImmuCell Corporation stock logo
ICCC
ImmuCell
$0.05$0.21+$0.16$0.21$5.40 million$10.36 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/AN/AN/AN/AN/A
ImmuCell Corporation stock logo
ICCC
ImmuCell
N/AN/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/AN/AN/AN/AN/A
Rafael Holdings, Inc. stock logo
RFL
Rafael
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
0.18
2.86
2.77
ImmuCell Corporation stock logo
ICCC
ImmuCell
0.24
4.82
2.60
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/A
2.27
2.27
Rafael Holdings, Inc. stock logo
RFL
Rafael
N/A
3.16
3.14

Institutional Ownership

CompanyInstitutional Ownership
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
96.51%
ImmuCell Corporation stock logo
ICCC
ImmuCell
13.47%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
3.28%
Rafael Holdings, Inc. stock logo
RFL
Rafael
11.30%

Insider Ownership

CompanyInsider Ownership
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
28.50%
ImmuCell Corporation stock logo
ICCC
ImmuCell
5.70%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2.50%
Rafael Holdings, Inc. stock logo
RFL
Rafael
32.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
17033.22 million23.75 millionOptionable
ImmuCell Corporation stock logo
ICCC
ImmuCell
709.05 million8.53 millionNot Optionable
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
206.88 million6.71 millionNot Optionable
Rafael Holdings, Inc. stock logo
RFL
Rafael
2052.00 million34.89 millionOptionable

Recent News About These Companies

Short Interest in Rafael Holdings, Inc. (NYSE:RFL) Rises By 89.0%
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/short-interest-in-rafael-holdings-inc-nyserfl-rises-by-890-2026-07-30/
Head-To-Head Contrast: Oncology Pharma (OTCMKTS:ONPH) vs. Rafael (NYSE:RFL)
July 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30929540
Rafael Holdings, Inc. (NYSE:RFL) Sees Large Growth in Short Interest
July 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/rafael-holdings-inc-nyserfl-sees-large-growth-in-short-interest-2026-07-16/
Rafael Holdings Inc Share Price (RFL.US)
July 15, 2026  |  lse.co.ukhttps://www.lse.co.uk/SharePrice.html?shareprice=RFL.US
Rafael Holdings Insider Trading Activity | NYSE:RFL | Benzinga
July 2, 2026  |  benzinga.comhttps://www.benzinga.com/quote/RFL/insider-trades
Rafael Holdings: The Second Half Of Calendar 2026 Could Define This Company Forever
June 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4918451-rafael-holdings-second-half-of-calendar-2026-could-define-this-company
Rafael Holdings (NYSE:RFL) Stock, Short Interest Report
June 25, 2026  |  benzinga.comhttps://www.benzinga.com/quote/RFL/short-interest
Rafael Holdings (NYSE: RFL) - Share Price and Research
June 25, 2026  |  intelligentinvestor.com.auI
Rafael B Stock Price History
June 11, 2026  |  investing.comhttps://www.investing.com/equities/rafael-b-historical-data
Rafael Holdings, Inc. Reports Q3 Fiscal 2026 Financial Results and Progress on Phase 3 TransportNPC™ Trial
June 11, 2026  |  quiverquant.comQ
Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results
June 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/11/3310357/0/en/rafael-holdings-reports-third-quarter-fiscal-2026-financial-results.html
Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick ...
June 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/rafael-holdings-announces-completion-last-113000912.html
Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
June 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/10/3309598/0/en/rafael-holdings-announces-completion-of-last-patient-last-visit-for-pivotal-phase-3-transportnpc-study-evaluating-trappsol-cyclo-for-the-treatment-of-niemann-pick-disease-type-c.html
Rafael Holdings Insider Ups Holding By 1,810% During Year
April 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/rafael-holdings-insider-ups-holding-142622929.html
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve ...
April 22, 2026  |  caledonianrecord.comC
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”
April 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/rafael-holdings-announces-patent-licensing-agreement-with-mit-for-small-molecules-to-improve-myelination-in-apoe4-positive-alzheimer-s-disease-1036048049
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”
April 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/22/3278798/0/en/rafael-holdings-announces-patent-licensing-agreement-with-mit-for-small-molecules-to-improve-myelination-in-apoe4-positive-alzheimer-s-disease.html
Rafael Holdings Inc. Wt
April 4, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/rfl.wt/company-people
Rafael Holdings, Inc.: Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results
March 17, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/67960421-rafael-holdings-inc-rafael-holdings-reports-second-quarter-fiscal-2026-financial-results-399.htm
Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results
March 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/16/3256686/0/en/rafael-holdings-reports-second-quarter-fiscal-2026-financial-results.html
Rafael Holdings (NYSE:RFL) Short Interest Falls on NYSE Composite
March 1, 2026  |  kalkinemedia.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

Fortress Biotech stock logo

Fortress Biotech NASDAQ:FBIO

$2.79 +0.07 (+2.57%)
Closing price 08/5/2026 04:00 PM Eastern
Extended Trading
$2.78 -0.01 (-0.36%)
As of 08/5/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

ImmuCell stock logo

ImmuCell NASDAQ:ICCC

$10.75 -0.32 (-2.89%)
Closing price 08/5/2026 04:00 PM Eastern
Extended Trading
$10.72 -0.04 (-0.33%)
As of 08/5/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Plus Therapeutics stock logo

Plus Therapeutics NASDAQ:PSTV

$3.96 +0.44 (+12.50%)
As of 08/4/2026

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Rafael stock logo

Rafael NYSE:RFL

$2.06 +0.19 (+10.37%)
Closing price 08/5/2026 03:59 PM Eastern
Extended Trading
$2.04 -0.02 (-1.16%)
As of 08/5/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas